Compare EPSN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | ACET |
|---|---|---|
| Founded | 2005 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 83.3M |
| IPO Year | 2018 | 2017 |
| Metric | EPSN | ACET |
|---|---|---|
| Price | $6.18 | $8.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $48.33 |
| AVG Volume (30 Days) | ★ 134.3K | 105.1K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.20 | $0.46 |
| 52 Week High | $6.65 | $9.97 |
| Indicator | EPSN | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 62.01 | 45.08 |
| Support Level | $5.78 | $8.62 |
| Resistance Level | $6.54 | $9.67 |
| Average True Range (ATR) | 0.21 | 0.54 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 74.75 | 13.33 |
Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).